AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceNamed GroupsHealth Care
LeukemiaLeukemia, Myeloid, AcuteLiver TransplantationTransplantation, HomologousLeukemia, Biphenotypic, AcuteBone Marrow TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaKidney TransplantationHematopoietic Stem Cell TransplantationLeukemia, LymphoidAcute DiseaseLeukemia, Monocytic, AcuteTransplantation, AutologousHeart TransplantationLeukemia, Lymphocytic, Chronic, B-CellLung TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveStem Cell TransplantationLeukemia, ExperimentalTransplantation ConditioningGraft SurvivalOrgan TransplantationTissue DonorsGraft vs Host DiseaseGraft RejectionTreatment OutcomeMyeloid-Lymphoid Leukemia ProteinPancreas TransplantationCytarabineIslets of Langerhans TransplantationBone MarrowTransplantation ChimeraTransplantationTransplantation ImmunologyLeukemia Virus, MurineLeukemia, MyeloidCell TransplantationRecurrenceRemission InductionCord Blood Stem Cell TransplantationImmunosuppressive AgentsLeukemia, T-CellRetrospective StudiesGene Expression Regulation, LeukemicTime FactorsLeukemia, B-CellHistocompatibility TestingTransplantation, IsogeneicHematologic NeoplasmsLiving DonorsLeukemia, Myelomonocytic, AcuteLeukemia, Radiation-InducedTransplantation, HeterotopicWhole-Body IrradiationHeart-Lung TransplantationKaryotypingPeripheral Blood Stem Cell TransplantationMyelodysplastic SyndromesPrognosisSurvival AnalysisSurvival RateMoloney murine leukemia virusAntineoplastic AgentsLeukemia, Megakaryoblastic, AcuteAntineoplastic Combined Chemotherapy ProtocolsFollow-Up StudiesTissue and Organ ProcurementLeukemia-Lymphoma, Adult T-CellLeukemia, Hairy CellDaunorubicinHematopoietic Stem CellsTransplantation ToleranceImmunophenotypingLeukemia L1210HL-60 CellsImmunosuppressionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemic InfiltrationLeukemia Virus, BovineLeukemia Virus, FelineBusulfanLiver FailureHistocompatibilityFetal Tissue TransplantationLeukemia, Promyelocytic, AcutePreleukemiaCyclophosphamideCombined Modality TherapyGraft vs Leukemia EffectLymphomaTransplantation, HeterologousIdarubicinDisease-Free SurvivalCyclosporineSkin TransplantationFusion Proteins, bcr-ablPostoperative ComplicationsChromosome AberrationsBlast CrisisCell Differentiation
Hematopoietic cellBlood and Marrow TransplantationChemotherapyMyelogenousCell TransplantationGraft-versus-HSCTRemission2023GVHDAutologous TransplantationPromyelocyticLymphomaMyelocytic leukemiaMalignanciesConditioning regimensSurvivalDonorRefractory acuteDiagnosisOutcomesStem cellLymphocyticMarrowInfants With Acute LymphoblTotal-body irradiErythroid leukemiaSymptoms of acute myeloidPediatric acutePost-transplantationUnderwentTreatment
Hematopoietic cell17
  • We sought to confirm the prognostic importance of simple clinically available biomarkers of C-reactive protein, serum albumin, and ferritin prior to allogeneic hematopoietic cell transplantation. (haematologica.org)
  • 6 Comorbidity determined by the hematopoietic cell transplantation-comorbidity index (HCT-CI), 7 predicts for worse survival, generally through higher TRM. (haematologica.org)
  • This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. (survivornet.com)
  • TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0. (survivornet.com)
  • Introduction: In the United States, autologous hematopoietic cell transplantation (autoHCT) has fallen out of favor over chemotherapy consolidation for non-high-risk acute myeloid leukemia (AML) when allogeneic hematopoietic cell transplantation (alloHCT) is unfeasible, which is common in racial minorities because of donor registry under-representation and socioeconomic challenges. (elsevierpure.com)
  • Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. (ox.ac.uk)
  • Autologous hematopoietic cell transplantation for adult acute myeloid leukemia: An obsolete or resurfacing concept? (umn.edu)
  • Dive into the research topics of 'Autologous hematopoietic cell transplantation for adult acute myeloid leukemia: An obsolete or resurfacing concept? (umn.edu)
  • Reduced-intensity conditioning/nonmyeloablative conditioning regimens are increasingly used in allogeneic hematopoietic cell transplantation (HCT). (elsevierpure.com)
  • NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. (sagepub.com)
  • Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. (sagepub.com)
  • Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. (sagepub.com)
  • Hematopoietic cell transplantation (HCT) is an integral part of the treatment of acute myeloid leukemia (AML). (apbmt.org)
  • Hematopoietic cell transplantation (HCT) is an effective treatment in patients with acute myeloid leukemia (AML). (apbmt.org)
  • The Japanese Society of Hematopoietic Cell Transplantation (JSHCT) has been conducting a nationwide survey on HCT since 1993, in which HCTs performed at participating centers are registered with the JSHCT every year. (apbmt.org)
  • A respected specialist in the field, Dr. Smith is a professor and chair of City of Hope's Department of Hematology & Hematopoietic Cell Transplantation . (cityofhope.org)
  • Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). (cityofhope.org)
Blood and Marrow Transplantation1
Chemotherapy12
  • TRANSPLANTATION: 2-Drug Combination Myeloablative Chemotherapy followed by Radiotherapy followed by Hematopoietic Rescue plus GVHD Prophylaxis. (knowcancer.com)
  • Autologous transplantation conferred relapse-free and overall survival benefit over chemotherapy consolidation alone, the current standard in the United States, and it might constitute a valuable option for ethnic/racial minorities. (elsevierpure.com)
  • We conclude that high-dose chemotherapy with busulfan and cyclophosphamide, followed by allogeneic-marrow transplantation, can produce long-term remission of acute leukemia. (johnshopkins.edu)
  • Chemotherapy with high-dose busulfan and cyclophosphamide before transplantation provides an effective alternative to cyclophosphamide and total-body irradiation before transplantation for the treatment of acute nonlymphocytic leukemia. (johnshopkins.edu)
  • Patients with acute myeloid leukemia (AML) often have an extended duration of neutropenia during intensive induction chemotherapy, consolidation chemotherapy, and hematopoietic stem cell transplantation (SCT). (johnshopkins.edu)
  • A significant portion of patients with acute myelogenous leukemia (AML) can now be cured with chemotherapy. (hematology.org)
  • For example, people who have stem cell transplantation go through intensive chemotherapy before treatment. (clevelandclinic.org)
  • Newer studies with intensive multiagent chemotherapy (eg, the CALGB [Cancer and Leukemia Group B]- 8811 and hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone] regimens and the ALL-2 regimen) plus the addition of TKIs for Ph+ ALL and rituximab for CD20-positive ALL have resulted in 3-y survivals of 50% or more in adults. (medscape.com)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
  • The use of consolidation chemotherapy in acute lymphoblastic leukemia (ALL) is supported by several studies. (medscape.com)
  • Treatment includes chemotherapy to achieve remission plus additional chemotherapy to avoid relapse and sometimes stem cell transplantation. (msdmanuals.com)
  • AML (Acute Myeloid Leukemia) is a blood cancer (haematological malignancy), and the standard way of treating older AML patients is chemotherapy. (lu.se)
Myelogenous4
  • Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. (uchicago.edu)
  • Acute myelogenous leukemia (AML) is a blood cancer that affects white blood cells, red blood cells, and/or platelets. (oncolink.org)
  • Role of signal transduction inhibition in treatment of acute myelogenous leukemia/myelodysplasia. (rochester.edu)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
Cell Transplantation42
Graft-versus-7
  • Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal organs and graft-versus-host disease (a complication after transplantation in which donor's immune cells recognize the host as foreign and attack the recipient's tissues). (survivornet.com)
  • Acute graft-versus-host disease and viral pneumonia were the major causes of death. (johnshopkins.edu)
  • UCBT at first CR and UCBT after 2007 were associated with good survival, while grade II-IV acute graft-versus-host disease (GVHD) was associated with low relapse rate but did not affect survival. (elsevierpure.com)
  • The cumulative incidence of treatment-related mortality (P=0.31), cumulative incidence of relapse (P=0.99), and proportion with acute-graft-versus-host disease (P=0.76) and chronic-graft-versus-host disease (P=0.68) were also not significantly different. (ox.ac.uk)
  • Although T-cell depletion is increasingly used to reduce the risk of graft-versus-host disease its impact on the graft-versus-leukemia effect and long-term outcome post-transplant is unknown. (ox.ac.uk)
  • Abstract Background In the setting of allogeneic human leukocyte antigen (HLA)-matched bone marrow transplantation, transplanting male patients with grafts from female donors has been associated with a higher incidence of graft-versus-host disease (GVHD) and of nonrelapse mortality (NRM). (uab.cat)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
HSCT9
  • This study analyzed the clinical outcomes of 119 pediatric acute leukemia patients who underwent haploidentical HSCT ( n =68) or human leukocyte antigen (HLA)-matched HSCT ( n =51). (blood-genomics.com)
  • There was no difference in transplantation-related toxicity (TRT) in terms of infection, hepatic dysfunction, oral mucositis, and engraftment syndrome between the haploidentical HSCT and HLA-matched HSCT groups. (blood-genomics.com)
  • Our objective was to compare MSD and MUD HSCT outcomes for children with acute leukemia in Argentina. (ox.ac.uk)
  • We included children with acute leukemia who underwent HSCT with either MSD or MUD between 2014 and 2019. (ox.ac.uk)
  • CONCLUSIONS: In Argentina, we did not show significant differences in outcomes between MSD and MUD HSCT for children with high-risk leukemia. (ox.ac.uk)
  • We performed absolute quantification of BAALC copy numbers in peripheral blood prior (median 7 days) to HSCT in complete remission (CR) or CR with incomplete peripheral recovery in 82 acute myeloid leukemia patients using digital droplet PCR (ddPCR) technology. (oncotarget.com)
  • Evaluation of pre-HSCT BAALC / ABL1 copy numbers in peripheral blood by ddPCR represents a feasible and rapid way to identify acute myeloid leukemia patients at high risk of early relapse after HSCT. (oncotarget.com)
  • In the future, prospective studies should evaluate whether acute myeloid leukemia patients with high pre-HSCT BAALC / ABL1 copy numbers benefit from additional treatment before or early intervention after HSCT. (oncotarget.com)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
Remission8
  • The study population consisted of 784 adults with acute myeloid leukemia in remission or myelodysplastic syndromes undergoing unrelated donor transplant reported to the Center for International Blood and Marrow Transplant Research. (haematologica.org)
  • Estimate rates of acute and chronic GvHD, infections, complete remission and neutrophil recovery. (survivornet.com)
  • This initial treatment aims to clear as many leukemia cells as possible in the blood and bone marrow and to induce remission. (medicalnewstoday.com)
  • This puts the leukemia into remission. (medlineplus.gov)
  • Fifty-one patients with acute nonlymphocytic leukemia (16 with end-stage disease, 17 in second or third remission or in early relapse, and 18 in first remission) were given infusions of HLA-identical sibling marrow after cytoreduction with high doses of busulfan and cyclophosphamide. (johnshopkins.edu)
  • Survival was favorably affected by younger age and transplantation during first remission. (johnshopkins.edu)
  • We retrospectively analyzed data from 475 children and adolescents receiving UCBT with myeloablative conditioning for acute lymphoblastic leukemia (ALL) in complete remission (CR), based on a nationwide registry. (elsevierpure.com)
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. (sagepub.com)
20231
  • Leukemia research 2023 9 134 107390. (cdc.gov)
GVHD7
  • Complications: including acute/chronic GVHD, infection and delayed engraftment. (survivornet.com)
  • The cumulative incidence of acute GVHD, non-relapse mortality (NRM), and graft-versus-host relapse-free survival (GRFS) were similar in both groups. (blood-genomics.com)
  • Furthermore, grade II-IV acute GVHD was associated with good LFS and low relapse rate, without high NRM, in patients receiving 5/6 HLA-matched UCBT. (elsevierpure.com)
  • Acute and chronic toxicities were primarily related to GVHD, infection and relapse rather than to TBI. (nature.com)
  • Results In comparison with other gender combination, male patients given female UCB (n = 131) had a trend for a higher incidence of grades II-IV acute GVHD (33 versus 25 %, P = 0.08), a trend for a higher incidence of NRM (41 versus 33 %, P = 0.06), and a lower leukemia-free (LFS, 30 versus 41 %, P = 0.01) and overall survival (OS, 33 versus 45 %, P = 0.008). (uab.cat)
  • Conclusions Our data suggest that male patients transplanted with female UCB might have higher risk of acute GVHD and of NRM leading to worse LFS and OS. (uab.cat)
  • Twenty-three patients experienced acute GVHD and 17 developed chronic GVHD. (medscimonit.com)
Autologous Transplantation1
Promyelocytic6
  • Describe the unique features of acute promyelocytic leukemia (AML M3), including the morphologic appearance of the promyelocyte, hemorrhagic complications, chromosomal abnormality, and treatment with induction therapy and all trans retinoic acid. (hematology.org)
  • The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO) into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management and outcome of this disease. (nih.gov)
  • Acute promyelocytic leukemia (APL) is a distinct variant of acute myeloid leukemia (AML). (medscape.com)
  • We describe the first case of a genetically diagnosed acute promyelocytic leukemia presenting with nephrotic range proteinuria that resolved with induction therapy with ATRA and ATO and performed a comprehensive review. (karger.com)
  • Acute promyelocytic leukemia is an important subtype of AML. (msdmanuals.com)
  • Acute promyelocytic leukemia affects a younger age group (median age 31 years) and particular ethnicity (Hispanic people). (msdmanuals.com)
Lymphoma6
  • The image below shows pre-B-cell lymphoblastic leukemia/lymphoma (B-ALL). (medscape.com)
  • 1 Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan. (nih.gov)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against blood cancer. (lls.org)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)
  • Patients with Burkitt leukemia/lymphoma are treated with regimens specific for this diagnosis. (medscape.com)
Myelocytic leukemia2
Malignancies3
  • As an Immune checkpoint blockade therapy (ICB), nivolumab has demonstrated efficacy in Acute Myeloid Leukemia (AML) and various other malignancies. (pensoft.net)
  • In a WHO proposal the blastic leukemias that are limited to the erythroid series are designated pure erythroid malignancies. (wikipedia.org)
  • The acute leukemias are aggressive malignancies that originate in a hematopoietic stem cell and are rapidly fatal without immediate treatment. (hematology.org)
Conditioning regimens2
  • Dr Craddock discusses the development of both novel conditioning regimens and post-transplantation strategies aimed at reducing the risk of disease relapse. (ox.ac.uk)
  • BACKGROUND: Reduced intensity conditioning regimens permit the delivery of a potentially curative graft-versus-leukemia effect in older patients with acute myeloid leukemia. (ox.ac.uk)
Survival4
  • In the total patient cohort, 5-year leukemia-free survival (LFS) and overall survival (OS) rates after UCBT were 61.1% and 67.7%, respectively. (elsevierpure.com)
  • DESIGN AND METHODS: We have characterized pre- and post-transplant factors determining overall survival in 168 patients with acute myeloid leukemia transplanted using an alemtuzumab based reduced intensity conditioning regimen with a median duration of follow-up of 37 months. (ox.ac.uk)
  • and lower survival inmale patients transplanted with female unrelated cord blood - A report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Comm. (uab.cat)
  • Fiere et al compared consolidation therapy with daunorubicin and cytosine arabinoside (Ara-C) versus no consolidation therapy in adults with ALL, demonstrating a 38% 3-year, leukemia-free survival rate for subjects receiving consolidation and maintenance therapy compared with 0% for those receiving maintenance therapy without consolidation. (medscape.com)
Donor3
  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (sagepub.com)
  • Various factors including age, sex, performance status (PS), disease status, cytogenetic risk, donor type, graft source, sex mismatch between the donor and the recipient, and year of transplantation were all shown to impact OS 2 . (apbmt.org)
  • While both treatments help your bone marrow to develop new blood cells, studies show allogeneic stem cell transplantations work by causing the donor cells to attack unhealthy cells. (clevelandclinic.org)
Refractory acute1
  • Immunotherapies, such as CAR-T cellular therapy, have been rapidly developed, especially for refractory acute lymphoblastic leukemia. (blood-genomics.com)
Diagnosis6
  • See the Childhood Acute Lymphoblastic Leukemia: Diagnosis, Management, and Complications slideshow to help recognize and treat this disease and its associated complications. (medscape.com)
  • After multivariable adjustment , statistically significant associations between primary resistance, pre- transplantation measurable residual disease , DNMT3A mutation , or white blood cell count at diagnosis and early relapse were observed. (bvsalud.org)
  • High BAALC expression levels at acute myeloid leukemia diagnosis have been linked to adverse outcomes. (oncotarget.com)
  • The identification of cytogenetic, molecular, and clinical factors impacting on outcome at acute myeloid leukemia (AML) diagnosis improved risk stratification [ 1 , 2 ]. (oncotarget.com)
  • 2012. According to international standards, cytogenetic and molecular examination determined that this form of leukemia was "poor risk" at the time of diagnosis. (cdc.gov)
  • Leukemia and 25.71% had Acute Myeloid Leukemia as the main diagnosis. (bvsalud.org)
Outcomes2
  • We compared outcomes of consolidation strategies in a minority-rich cohort in the Bronx with limited access to allogeneic transplantation. (elsevierpure.com)
  • The aim of the current analysis was to compare transplantation outcomes in male patients given female unrelated cord blood (UCB) versus other gender combinations. (uab.cat)
Stem cell3
  • He also identifies the emerging importance of leukemia stem cell biology in determining both response to therapy and relapse risk in AML. (ox.ac.uk)
  • What's the difference between allogeneic and autologous stem cell transplantations? (clevelandclinic.org)
  • However, an alternative is to perform bone marrow or stem cell tx (transplantation). (lu.se)
Lymphocytic2
  • OBJECTIVES: I. Assess the feasibility and outcome of intensified induction/consolidation followed by intensified re-induction/re-intensification in infants less than 1 year of age with newly diagnosed acute lymphocytic leukemia (ALL). (knowcancer.com)
  • Acute lymphoblastic leukemia (acute lymphocytic leukemia, ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. (medscape.com)
Marrow16
Infants With Acute Lymphobl1
Total-body irradi1
  • Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. (nature.com)
Erythroid leukemia5
Symptoms of acute myeloid1
Pediatric acute3
  • See also Pediatric Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia (AML) . (medscape.com)
  • Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy[J]. Curr Opin Pediatr , 2020, 32(1): 57−66. (blood-genomics.com)
  • Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw , 2020, 18(1): 81−112. (blood-genomics.com)
Post-transplantation1
  • At post transplantation day plus 3, antibiotic drug therapy was switched from piperacillin/tazobactam to meropenem. (cdc.gov)
Underwent1
Treatment7
  • Recent data indicate that high BAALC expression levels may also be used as marker for residual disease following acute myeloid leukemia treatment. (oncotarget.com)
  • As with acute lymphoblastic leukemia, the successful management of patients with AML requires a therapeutic strategy determined by careful assessment of individual prognosis, aggressive supportive therapy, and early recognition and treatment of complications. (hematology.org)
  • The treatment is designed to wipe out the abnormally functioning leukemia cells. (oncolink.org)
  • The treatment regimen for patients with ALL is determined primarily by the Philadelphia chromosome status of the leukemia and the age of the patient. (medscape.com)
  • Acute lymphoblastic leukemia (ALL) is best treated by physicians who have significant experience in the treatment of patients with acute leukemia. (medscape.com)
  • Patients admitted to hospitals that lack appropriate blood product support facilities, leukapheresis capabilities, or physicians and nurses familiar with the treatment of patients with leukemia should be transferred to an appropriate (generally, tertiary care) hospital. (medscape.com)
  • See also Acute Lymphoblastic Leukemia Treatment Protocols . (medscape.com)